Filter Results
Clinical Studies
Results filtered:Study status:
Open
Contact Us for the Latest Status
Closed for Enrollment
Open
-
A Phase 2/3 Efficacy And Safety Study Of KPL-387 Treatment In Participants With Recurrent Pericarditis
Rochester, Minn.
This study is being done to demonstrate whether KPL-387 is an effective and safe treatment for recurrent pericarditis.
-
A Phase 2a, Open-Label Pilot Study To Evaluate The Safety/Tolerability, Efficacy, Pharmacokinetics, And Pharmacodynamics Of VTX2735 In Participants With Recurrent Pericarditis
Rochester, Minn.
This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Recurrent Pericarditis (RP).
Cohort A will include up to 30 participants and will consist of the following:
* A 30-day Screening Period (to see if a participant qualifies for the study)
* A 6-week Open Label Treatment Period - participant receives VTX2735 Dose A
* A 7-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose A
* An 11-week Once Daily Treatment Period (if a participant meets criteria for this treatment period) - participant receives VTX2735 Dose B
* A 14-day Follow-Up Period
Cohort B will include up to 20 participants and will consist of the following:
* A 30-day Screening Period (to see if a participant qualifies for the study)
* A 6-week Open Label Treatment Period - participant receives VTX2735 Dose B or C
* An 18-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose B or C
* A 14-day Follow-Up Period
-
IMpAct Of CardiolRxTM OVer 6 Months Following IL-1 Blocker Cessation In PERICarditis Patients - MAVERIC A Randomized, Double-blind, Placebo-controlled Trial
Scottsdale/Phoenix, Ariz.,
Jacksonville, Fla.,
Rochester, Minn.
Multi-center, randomized, double-blind, placebo-controlled, phase-3 Trial. Patients with a history of recurrent pericarditis who are being treated with an IL-1 blocker for at least 12 months, scheduled to be discontinued, will be approached for potential trial participation.
Double-blind treatment will be initiated 10 - 16 days prior to the last scheduled dose of the IL-1 blocker and continued for 24 weeks.
The objective is to assess whether patients who discontinue therapy with an IL-1 blocker for recurrent pericarditis remain free of pericarditis recurrence while receiving CardiolRx.
Contact Us for the Latest Status
Closed for Enrollment
-
An Open-Label Pilot Study Of KPL-914 In Recurrent Pericarditis
Jacksonville, Fla.,
Rochester, Minn.
The study is comprised of 5 Parts:
- Part 1 enrolls symptomatic subjects with recurrent idiopathic pericarditis (RIP) with an elevated marker of systemic inflammation (C-reactive protein [CRP] > 1mg/dL).
- Part 2 enrolls symptomatic subjects with RIP with CRP ≤1 mg/dL which, in the opinion of the investigator, can be attributed to concomitant medications (e.g., corticosteroids) and with
- pericardial inflammation present on cardiac magnetic resonance imaging (MRI) confirmed by the imaging core lab.
- Part 3 enrolls subjects with corticosteroid-dependent RIP not experiencing symptoms which would meet the diagnostic criteria for a flare of pericarditis.
- Part 4 enrolls symptomatic subjects with recurrent post pericardiotomy syndrome (PPS) with an elevated marker of systemic inflammation (CRP > 1mg/dL).
- Part 5 enrolls subjects with corticosteroid-dependent recurrent PPS not experiencing
-
Impact Of CardiolRxTM On Recurrent Pericarditis An Open Label Pilot Study
Rochester, Minn.
The purpose of this study is to evaluate the effect of treatment with CardiolRxTM on recurrent pericarditis.
-
Phase 3, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study With Open-label Extension, To Assess The Efficacy And Safety Of Rilonacept Treatment In Subjects With Recurrent Pericarditis
Rochester, Minn.
The purpose of this study is to assess the effectiveness and safety of rilonacept treatment in subjects with recurrent pericarditis.
-
RESONANCE–REgiStry Of the NAtural history of recurreNt periCarditis in pEdiatric and adult patients (RESONANCE)
Rochester, Minn.
The purpose of this study is to further the understanding of the natural history of recurrent pericarditis (RP), as well as document RP-related clinical, health-related quality of life (HRQoL), and economic burden and will assist the medical community to refine or develop data-driven recommendations for clinical management of RP patients to optimize clinical outcomes. It also aims to generate data in support of the impact of rilonacept on clinical outcomes in a real-world population.
.